 Connection
David Camidge to Macrocyclic Compounds
This is a "connection" page, showing publications David Camidge has written about Macrocyclic Compounds.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.112 |
|
|
|
-
Drilon A, Cho BC, Camidge DR, Nagasaka M, Besse B, Solomon B, Goto K, Wolf J, Popat S, Felip E, Yang N, de Langen AJ, Lu S, Velcheti V, Lin AL, Calvet CY, Li L, Tschaika M, Afsar S, Yang H, Lin JJ. Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. Oncologist. 2026 May 08; 31(6).
Score: 0.061
-
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 01 11; 390(2):118-131.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|